Dynavax Technologies Corporation (DVAX) Stock Analysis

Dynavax Technologies Corporation (DVAX) Healthcare & Pipeline Overview

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company specializing in vaccine development, notably HEPLISAV-B for hepatitis B. The company leverages its proprietary adjuvant, CpG 1018, to enhance vaccine efficacy. With a focus on infectious diseases, Dynavax operates within the competitive specialty vaccine market, serving adult populations in the US and Europe.

What Is the Investment Thesis for DVAX?

The increasing awareness of hepatitis B and the advantages of HEPLISAV-B's two-dose regimen are expected to drive market penetration. Dynavax's gross margin of 83.2% indicates strong profitability potential as sales scale. Collaborations with Valneva, Serum Institute of India, and Merck provide additional revenue streams and validation of the adjuvant technology. However, the company's negative profit margin of -13.1% highlights the need for continued focus on cost management and achieving sustained profitability. Successful execution of partnerships and expansion into new markets are critical for long-term value creation.

Based on FMP financials and quantitative analysis

DVAX Key Highlights

HEPLISAV-B is a hepatitis B vaccine approved for adults aged 18 years and older in the United States and Europe.

• Dynavax manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B, enhancing the immune response to vaccines.
• The company has a collaboration agreement with Valneva Scotland Limited to develop new vaccines.
• Dynavax has a sublicense agreement with Merck, Sharp & Dohme Corp. for the use of its adjuvant technology.
• Dynavax reported a gross margin of 83.2%, indicating strong profitability potential.

Who Are DVAX's Competitors?

DVAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DVAX's Key Strengths?

Innovative HEPLISAV-B vaccine with a convenient two-dose regimen.

• Proprietary CpG 1018 adjuvant technology enhances vaccine efficacy.
• Established collaborations with leading pharmaceutical companies.
• Strong gross margin indicates profitability potential.

What Are DVAX's Weaknesses?

Negative profit margin requires focus on cost management.

• Reliance on HEPLISAV-B sales for revenue generation.
• Competition from established pharmaceutical companies with broad vaccine portfolios.
• Limited geographic presence compared to larger competitors.

What Could Drive DVAX Stock Higher?

Potential regulatory approvals for HEPLISAV-B in new geographic markets.

• Continued expansion of HEPLISAV-B sales in the United States and Europe.
• Progress in collaborations with Valneva, Serum Institute of India, and Merck.
• Data readouts from clinical trials evaluating new vaccine candidates using CpG 1018 adjuvant.

What Are the Key Risks for DVAX?

Negative return on equity (-8.1%) — the business is not currently generating profit on shareholder capital.

• Insider selling — insiders were net sellers of roughly $14.1M recently.
• Competition from existing hepatitis B vaccines and new entrants.
• Regulatory hurdles and delays in obtaining approvals for new products.
• Patent expiration and generic competition.
• Dependence on HEPLISAV-B sales for revenue generation.
• Changes in public health recommendations and vaccination schedules.

What Are the Growth Opportunities for DVAX?

• Growth opportunity 1: Expanding HEPLISAV-B Market Share: HEPLISAV-B has a significant opportunity to capture a larger share of the hepatitis B vaccine market. The increasing awareness of the disease and the advantages of a two-dose regimen compared to traditional three-dose vaccines position HEPLISAV-B for growth. Focused marketing and sales efforts targeting high-risk populations and healthcare providers can drive adoption.
• Growth opportunity 2: Leveraging CpG 1018 Adjuvant Technology: Dynavax's CpG 1018 adjuvant technology has broad applications in vaccine development. Collaborations with other companies, such as Valneva and Serum Institute of India, demonstrate the potential for this technology to enhance the efficacy of various vaccines. Expanding partnerships and licensing agreements can generate additional revenue streams and establish Dynavax as a key player in the adjuvant market. The global adjuvants market is expected to grow, driven by the increasing demand for more effective vaccines.
• Growth opportunity 3: Geographic Expansion of HEPLISAV-B: While HEPLISAV-B is currently approved in the United States and Europe, there is potential for geographic expansion into other markets. Obtaining regulatory approvals in additional countries can significantly increase the addressable market for HEPLISAV-B. This expansion requires navigating regulatory pathways and establishing distribution networks in new regions. The global market for hepatitis B vaccines is substantial, offering opportunities for Dynavax to increase its global footprint.
• Growth opportunity 4: Development of New Vaccine Candidates: Dynavax can leverage its expertise in vaccine development to create new vaccine candidates targeting other infectious diseases. This involves identifying unmet needs in the vaccine market and developing innovative solutions using its adjuvant technology. Successful development and commercialization of new vaccines can diversify Dynavax's product portfolio and reduce its reliance on HEPLISAV-B. The global vaccine market is constantly evolving, with ongoing research and development efforts focused on addressing emerging infectious diseases.
• Growth opportunity 5: Strategic Acquisitions and Partnerships: Dynavax can pursue strategic acquisitions and partnerships to expand its product portfolio and technological capabilities. Acquiring companies with complementary technologies or products can accelerate growth and diversify revenue streams. Partnerships with research institutions and other pharmaceutical companies can provide access to new vaccine candidates and development expertise. Strategic collaborations can enhance Dynavax's competitive position and drive long-term value creation.

What Are DVAX's Competitive Advantages?

• Proprietary CpG 1018 adjuvant technology enhances vaccine efficacy.
• HEPLISAV-B's two-dose regimen offers a convenient alternative to traditional three-dose vaccines.
• Established collaborations with leading pharmaceutical companies.
• Strong intellectual property protection for its products and technologies.

What Does DVAX Do?

Dynavax Technologies Corporation, founded in 1996 and headquartered in Emeryville, California, is a biopharmaceutical company focused on developing and commercializing innovative vaccines. Originally named Double Helix Corporation, the company rebranded to Dynavax Technologies Corporation in September 1996, marking a pivotal shift towards vaccine development. The company's flagship product is HEPLISAV-B, a hepatitis B vaccine approved for adults aged 18 years and older in the United States and Europe. HEPLISAV-B distinguishes itself through its high efficacy and a two-dose regimen, offering a convenient alternative to traditional three-dose vaccines. Dynavax also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B, which enhances the immune response to vaccines. This adjuvant technology is a key component of Dynavax's strategy, enabling collaborations with other companies for vaccine development. Dynavax has established collaborations with Valneva Scotland Limited, Serum Institute of India Pvt. Ltd., and Merck, Sharp & Dohme Corp., expanding the application of its adjuvant technology and broadening its market reach. The company's focus remains on addressing unmet needs in infectious diseases through innovative vaccine solutions.

What Products and Services Does DVAX Offer?

• Develops and commercializes novel vaccines.
• Markets HEPLISAV-B, a hepatitis B vaccine for adults.
• Manufactures and sells CpG 1018 adjuvant.
• Collaborates with other companies for vaccine development.
• Focuses on addressing unmet needs in infectious diseases.
• Seeks regulatory approvals for its products in various markets.

How Does DVAX Make Money?

• Develops and commercializes its own vaccines, such as HEPLISAV-B.
• Generates revenue from sales of HEPLISAV-B in the US and Europe.
• Out-licenses its CpG 1018 adjuvant technology to other companies.
• Receives milestone payments and royalties from collaborations.

What Industry Does DVAX Operate In?

Dynavax operates within the specialty vaccine market, a segment of the pharmaceutical industry characterized by high barriers to entry and significant regulatory oversight. The global vaccine market is experiencing growth driven by increasing awareness of infectious diseases and advancements in vaccine technology. Competition includes established pharmaceutical companies with broad vaccine portfolios. Dynavax differentiates itself through its HEPLISAV-B vaccine and its CpG 1018 adjuvant technology, which enhances vaccine efficacy. The market is also influenced by public health initiatives and government recommendations regarding vaccination schedules.

Who Are DVAX's Key Customers?

• Adults aged 18 years and older requiring hepatitis B vaccination.
• Healthcare providers who administer vaccines.
• Hospitals and clinics that offer vaccination services.
• Government agencies and public health organizations.

Dynavax Technologies Corporation (DVAX) Valuation Context

Valued at $1.82B, DVAX is classified as a small-cap stock.

DVAX Revenue & Earnings Trend

In Sep 2025, DVAX generated $94.9M in top-line revenue, marking a sequential decrease of 0.6%. The company recorded net income of $26.9M, with diluted EPS of $0.20. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, DVAX averaged $-0.10 in diluted EPS.

Company Profile

Dynavax Technologies Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO Ryan Spencer. DVAX has traded publicly since 2004.

Return on equity for Dynavax Technologies Corporation stands at -8.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.4%, the inverse of the P/E and a quick read on earnings relative to price.

Dynavax Technologies Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.37 places it in the grey zone, a middle ground that warrants monitoring.

Dynavax Technologies Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 329.5% below estimates on average.

Wall Street analysts project Dynavax Technologies Corporation revenue of about $380.1M for fiscal 2026, with EPS near $0.49.

The most recent 12 insider filings for Dynavax Technologies Corporation break down as 10 sales and 2 purchases. On net that is roughly 17.5M shares disposed (about $14.1M), a signal worth weighing alongside the fundamentals.

DVAX Financials

DVAX Latest News

Latest Dynavax Technologies Corporation Analysis

What Investors Ask About Dynavax Technologies Corporation (DVAX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources